Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

NanoCarrier

DB:3NQ
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3NQ
DB
¥13B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
  • NanoCarrier has significant price volatility in the past 3 months.
3NQ Share Price and Events
7 Day Returns
-7.7%
DB:3NQ
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-48.3%
DB:3NQ
-13.2%
DE Biotechs
-20.9%
DE Market
3NQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NanoCarrier (3NQ) -7.7% -8.7% -20.8% -48.3% -70.2% -81%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 3NQ underperformed the Biotechs industry which returned -13.2% over the past year.
  • 3NQ underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
3NQ
Industry
5yr Volatility vs Market

Value

 Is NanoCarrier undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NanoCarrier. This is due to cash flow or dividend data being unavailable. The share price is €1.68.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NanoCarrier's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NanoCarrier's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3NQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in JPY ¥-26.16
TSE:4571 Share Price ** TSE (2020-04-03) in JPY ¥204
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NanoCarrier.

DB:3NQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4571 Share Price ÷ EPS (both in JPY)

= 204 ÷ -26.16

-7.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoCarrier is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NanoCarrier is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NanoCarrier's expected growth come at a high price?
Raw Data
DB:3NQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NanoCarrier, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NanoCarrier's assets?
Raw Data
DB:3NQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in JPY ¥143.24
TSE:4571 Share Price * TSE (2020-04-03) in JPY ¥204
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:3NQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4571 Share Price ÷ Book Value per Share (both in JPY)

= 204 ÷ 143.24

1.42x

* Primary Listing of NanoCarrier.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoCarrier is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NanoCarrier's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NanoCarrier has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NanoCarrier expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoCarrier has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NanoCarrier expected to grow at an attractive rate?
  • Unable to compare NanoCarrier's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NanoCarrier's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare NanoCarrier's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3NQ Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3NQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3NQ Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-04-06
DB:3NQ Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-12-31 596 -1,485
2019-09-30 572 -1,634 -1,795
2019-06-30 600 -1,618
2019-03-31 496 -2,037 -1,808
2018-12-31 456 -2,245
2018-09-30 406 -4,218 -4,276
2018-06-30 266 -4,793
2018-03-31 259 -4,927 -5,416
2017-12-31 213 -5,551
2017-09-30 205 -3,013 -2,954
2017-06-30 215 -2,888
2017-03-31 218 -2,525 -2,676

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NanoCarrier is high growth as no earnings estimate data is available.
  • Unable to determine if NanoCarrier is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3NQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from NanoCarrier Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NQ Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-04-06
DB:3NQ Past Financials Data
Date (Data in JPY Millions) EPS *
2019-12-31 -26.16
2019-09-30 -34.59
2019-06-30 -33.82
2019-03-31 -39.13
2018-12-31 -49.64
2018-09-30 -96.34
2018-06-30 -109.85
2018-03-31 -125.37
2017-12-31 -128.53
2017-09-30 -68.41
2017-06-30 -66.89
2017-03-31 -62.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NanoCarrier will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine NanoCarrier's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. NanoCarrier's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. NanoCarrier's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess NanoCarrier's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NanoCarrier has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NanoCarrier performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NanoCarrier's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NanoCarrier does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NanoCarrier's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NanoCarrier's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NanoCarrier's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NanoCarrier Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NQ Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 596.00 -1,485.00 -92.00 1,793.00
2019-09-30 572.00 -1,795.00 180.00 1,793.00
2019-06-30 600.00 -1,618.00 324.00 1,793.00
2019-03-31 496.00 -1,808.00 363.00 1,793.00
2018-12-31 456.00 -2,245.00 -2,581.00 4,979.00
2018-09-30 406.00 -4,276.00 -558.00 4,979.00
2018-06-30 266.00 -4,793.00 -156.00 4,979.00
2018-03-31 259.00 -5,416.00 465.00 4,979.00
2017-12-31 213.00 -5,551.00 3,298.00 2,252.00
2017-09-30 205.00 -2,954.00 1,325.00 2,252.00
2017-06-30 215.00 -2,888.00 1,174.00 2,252.00
2017-03-31 218.00 -2,676.00 528.00 2,252.00
2016-12-31 298.00 -2,920.00 914.00 1,832.00
2016-09-30 313.00 -3,402.00 798.00 1,832.00
2016-06-30 269.00 -3,278.00 587.00 1,832.00
2016-03-31 243.00 -2,537.00 393.00 1,832.00
2015-12-31 405.00 -1,616.00 836.00 1,053.00
2015-09-30 377.00 -962.00 681.00 1,053.00
2015-06-30 631.00 -52.00 502.00 1,053.00
2015-03-31 675.00 -207.00 466.00 1,053.00
2014-12-31 386.00 -443.00 492.00 926.00
2014-09-30 458.00 -827.00 405.00 926.00
2014-06-30 379.00 -1,383.00 451.00 926.00
2014-03-31 472.00 -1,113.00 418.00 926.00
2013-12-31 616.00 -762.00 973.00 237.00
2013-09-30 599.00 -653.00 794.00 237.00
2013-06-30 513.00 -495.00 573.00 237.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NanoCarrier has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NanoCarrier has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NanoCarrier improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NanoCarrier's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NanoCarrier has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NanoCarrier's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NanoCarrier's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NanoCarrier is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NanoCarrier's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NanoCarrier's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NanoCarrier has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NanoCarrier Company Filings, last reported 3 months ago.

DB:3NQ Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 9,467.00 0.00 7,847.00
2019-09-30 9,422.00 0.00 8,064.00
2019-06-30 7,251.00 527.00 6,608.00
2019-03-31 5,879.00 2,475.00 6,566.00
2018-12-31 4,845.00 2,475.00 5,684.00
2018-09-30 5,688.00 2,475.00 6,208.00
2018-06-30 5,480.00 2,475.00 6,564.00
2018-03-31 4,660.00 2,475.00 6,407.00
2017-12-31 5,428.00 2,475.00 7,135.00
2017-09-30 8,062.00 2,475.00 9,630.00
2017-06-30 8,850.00 2,475.00 10,559.00
2017-03-31 10,066.00 2,475.00 11,769.00
2016-12-31 10,989.00 2,475.00 12,582.00
2016-09-30 10,966.00 2,475.00 12,576.00
2016-06-30 11,688.00 2,475.00 12,906.00
2016-03-31 12,127.00 3,000.00 13,760.00
2015-12-31 13,284.00 3,000.00 14,880.00
2015-09-30 13,624.00 0.00 12,941.00
2015-06-30 14,213.00 0.00 13,619.00
2015-03-31 14,500.00 0.00 13,771.00
2014-12-31 13,688.00 540.00 13,574.00
2014-09-30 13,480.00 540.00 10,364.00
2014-06-30 13,147.00 540.00 10,159.00
2014-03-31 13,595.00 540.00 7,246.00
2013-12-31 14,041.00 540.00 7,833.00
2013-09-30 5,110.00 540.00 5,359.00
2013-06-30 4,422.00 1,040.00 5,124.00
  • NanoCarrier has no debt.
  • NanoCarrier has no debt compared to 5 years ago when it was 3.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NanoCarrier has sufficient cash runway for more than 3 years based on current free cash flow.
  • NanoCarrier has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 16.1% each year.
X
Financial health checks
We assess NanoCarrier's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NanoCarrier has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NanoCarrier's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NanoCarrier dividends.
If you bought €2,000 of NanoCarrier shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NanoCarrier's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NanoCarrier's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3NQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3NQ Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NanoCarrier has not reported any payouts.
  • Unable to verify if NanoCarrier's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NanoCarrier's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NanoCarrier has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NanoCarrier's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NanoCarrier afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NanoCarrier has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NanoCarrier's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tetsuhito Matsuyama
TENURE AS CEO 0.4 years
CEO Bio

Mr. Tetsuhito Matsuyama is President & Director since November 2019 and had been the Chief Financial Officer and Head of Chief Executive Officer's Office at NanoCarrier Co., Ltd. since January 2015 until November 2019 and served as its Head of President's Office since January 2015 until November 2019. Mr. Matsuyama served as Representative Director at Nanotech Partners Limited. He served as Chief Executive Officer and President of Medical ProteoScope Co., Ltd. since May 2003. In April 1986, he joined Mitsubishi Corporation and served as its Chief Operating Officer and Chief Financial Officer since May 2003. Mr. Matsuyama served as Executive Officer of CSK Institute for Sustainability, Ltd. since October 2007. Since December 2014, he served as Advisor to NanoCarrier Co., Ltd. Since May 2010, Mr. Matsuyama served as, among others, General Manager of Business Development Division, Executive Officer and Chief Operating Officer of Overseas Business Group of Lawson Inc. Since November 2012, he served as, among others, Consultant, Senior Managing Director and Director of Nitto Boseki Co., Ltd. Mr. Matsuyama serves as a Director at NanoCarrier Co., Ltd. He served as a Director at Mitsubishi since May 2003.

CEO Compensation
  • Insufficient data for Tetsuhito to compare compensation growth.
  • Insufficient data for Tetsuhito to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Tetsuhito Matsuyama

TITLE
President & CEO
TENURE
0.4 yrs

Hiroyuki Hanada

TITLE
Chief Business Officer and Director
AGE
63
TENURE
11.8 yrs
Board of Directors Tenure

Average tenure and age of the NanoCarrier board of directors in years:

13.6
Average Tenure
63
Average Age
  • The average tenure for the NanoCarrier board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Hiroyuki Hanada

TITLE
Chief Business Officer and Director
AGE
63
TENURE
11.8 yrs

Ichiro Nakatomi

TITLE
Director
AGE
69
TENURE
23.8 yrs

Teruo Okano

TITLE
External Director
AGE
70
TENURE
23.8 yrs

Akira Ohashi

TITLE
External Director
AGE
76
TENURE
16.8 yrs

Atsushi Matsumura

TITLE
External Director
AGE
57
TENURE
8.1 yrs

Tomoyuki Fujisawa

TITLE
External Director
AGE
53
TENURE
5.8 yrs

Manish Mishra

TITLE
Director
TENURE
0.8 yrs

Mieko Nakayama

TITLE
Audit & Supervisory Board Member
AGE
57

Tadashi Morishima

TITLE
External Auditor
AGE
71
TENURE
20.5 yrs

Toshio Furuta

TITLE
External Auditor
AGE
57
TENURE
13.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NanoCarrier's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NanoCarrier has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company’s product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.

Details
Name: NanoCarrier Co., Ltd.
3NQ
Exchange: DB
Founded: 1996
¥115,109,348
66,057,375
Website: http://www.nanocarrier.co.jp
Address: NanoCarrier Co., Ltd.
Chuou 144-15,
226-39 Wakashiba,
Kashiwa,
Chiba, 277-0871,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4571 Common Shares The Tokyo Stock Exchange JP JPY 05. Mar 2008
DB 3NQ Common Shares Deutsche Boerse AG DE EUR 05. Mar 2008
Number of employees
Current staff
Staff numbers
42
NanoCarrier employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:03
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/19
Last earnings filing: 2020/02/14
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.